Seth M. Rubin

Seth M. Rubin

Auto-generated profile, based on publicly available information

Seth M. Rubin

Department of Chemistry and Biochemistry, University of California, Santa Cruz

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2013 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
FDFrederick A. Dick
Frederick A. Dick
SRSeth M. Rubin
Seth M. Rubin

4 September 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MSMegan M. Spence
Megan M. Spence
SRSeth M. Rubin
Seth M. Rubin
IDIvan E. Dimitrov
Ivan E. Dimitrov
ERE. Janette Ruiz
E. Janette Ruiz
DWDavid E. Wemmer
David E. Wemmer
PSPeter G. Schultz
Peter G. Schultz
The detection of biological molecules and their interactions is a significant component of modern biomedical research. In current biosensor technologies, simultaneous detection is limited to a small number of analytes by the spectral overlap of their signals. We have developed an NMR-based xenon biosensor that capitalizes on the enhanced signal-to-noise, spectral simplicity, and chemical-shift sensitivity of laser-polarized xenon to detect specific biomolecules at the level of tens of nanomoles. We present results using xenon “functionalized” by a biotin-modified supramolecular cage to detect biotin–avidin binding. This biosensor methodology can be extended to a multiplexing assay for multiple analytes.

1 May 2019 in Molecular Cell
Verified
Journal Article
Closed access
BTBenjamin R. Topacio
Benjamin R. Topacio
EZEvgeny Zatulovskiy
Evgeny Zatulovskiy
SCSandra Cristea
Sandra Cristea
SXShicong Xie
Shicong Xie
CTCarrie S. Tambo
Carrie S. Tambo
JSJan M. Skotheim
Jan M. Skotheim

17 September 2020 in Molecular Cell
Verified
Journal Article
Closed access
SRSeth M. Rubin
Seth M. Rubin
JSJulien Sage
Julien Sage
JSJan M. Skotheim
Jan M. Skotheim

1 January 2013 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
SRSeth M. Rubin
Seth M. Rubin

13 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
KGKeelan Z. Guiley
Keelan Z. Guiley
JSJack W. Stevenson
Jack W. Stevenson
KLKevin Lou
Kevin Lou
KBKrister J. Barkovich
Krister J. Barkovich
VKVishnu Kumarasamy
Vishnu Kumarasamy
SRSeth M. Rubin
Seth M. Rubin
Revised view of anticancer drug mechanism: A crystal structure of the active form of cyclin-dependent kinase 4 (CDK4) provides insight into regulation of the cell cycle and the mechanism of action of a drug used for breast cancer therapy. The protein p27 has been thought to act as a CDK inhibitor. Guiley et al. performed a structural analysis of active complexes of CDK4 with cyclin D1 (CycD1) and p27 (see the Perspective by Sherr). The results showed that p27 actually remodels the active site of CDK4 to allow full activation when p27 is phosphorylated on tyrosine (phosp27). Furthermore, they found that the breast cancer drug palbociclib, a CDK4 inhibitor, doesn't actually interact with active phosp27-CDK4-CycD1 trimers. Instead, it appears that the drug, which shows promise in the clinic, binds to inactive CDK4 monomers and prevents interaction with p27. Science , this issue p. eaaw2106 ; see also p. 1315